QSI Stock Risk & Deep Value Analysis
Quantum-Si Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About QSI Stock
We analyzed Quantum-Si Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran QSI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
QSI Risk Analysis & Red Flags
What Could Go Wrong
The company continues to burn substantial cash (over $100M annually) with minimal revenue. If Proteus commercial adoption is significantly slower than projected, Quantum-Si will require further dilutive capital raises at depressed share prices, potentially wiping out a substantial portion of shareholder value before the technology gains critical mass.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Low
Red Flags
- ⚠
FY2025 revenue declined 20.3% YoY, and Q1 2026 estimates project a 64.49% YoY decline, indicating a severe near-term revenue contraction.
- ⚠
Significant operating losses (-$111.6M EBITDA in FY2025) and negative net margin (-4,221%), necessitating substantial and ongoing capital raises.
- ⚠
Canaccord Genuity, a covering analyst, recently lowered its price target to $1.00, reflecting skepticism about the near-term commercial ramp.
- ⚠
Valuation multiples (P/S 113.1x) are exceptionally high relative to current revenue, making the stock highly sensitive to execution.
Upcoming Risk Events
- 📅
Q1 2026 earnings miss below already low expectations
- 📅
Slower-than-anticipated commercial ramp-up for Proteus platform
- 📅
Further significant delays in achieving positive operating cash flow
When to Reconsider
- 🚪
Exit if Q2 2026 revenue guidance shows no material improvement or further sequential decline, signaling deeper commercialization issues.
- 🚪
Sell if cash balance drops below $100M without a clear, non-dilutive financing plan.
- 🚪
Exit if Proteus launch is delayed by more than 6 months or initial customer feedback is overwhelmingly negative.
Unlock QSI Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Quantum-Si Inc (QSI) Do?
Market Cap
$207.32M
Sector
Healthcare
Industry
Medical Devices
Employees
149
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Visit Quantum-Si Inc WebsiteInvestment Thesis
Quantum-Si is an aggressive, long-term investment targeting the multi-billion-dollar proteomics market. Its proprietary digital protein sequencing technology, particularly the upcoming Proteus platform, has the potential to be truly disruptive, enabling new discoveries in biology and medicine. Despite significant near-term financial challenges (declining revenue, high cash burn, unprofitability), the recent successful demonstration of Proteus technology validates the company's execution on its strategic pivot. This is a high-risk, high-reward play betting on the company's ability to achieve future market leadership through technological innovation.
Is QSI Stock Undervalued?
Unlock the full AI analysis for QSI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
QSI Price Targets & Strategy
12-Month Target
$1.50
Bull Case
$3.00
Bear Case
$0.50
Valuation Basis
2.5x current market cap of $0.21B for a disruptive biotech gaining initial traction in a large TAM, reflecting high P/S multiple (~60x FY26 est. if revenue hits $5M).
Entry Strategy
Dollar-cost average between $0.80-$1.00, ideally on dips towards the 52-week low if Q1 earnings are disappointing but Proteus outlook remains positive.
Exit Strategy
Take 50% profit at $2.50-$3.00; Stop loss if sustained close below $0.70 (technical support level).
Portfolio Allocation
2-5% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is QSI Financially Healthy?
Valuation
P/E Ratio
4.55
Forward P/E
122.01
PEG Ratio
2.86
Price/Book
1.82
Price/Sales
104.63
Profitability
Gross Margin
47.33%
Operating Margin
-4765.97%
Net Margin
-4160.06%
Return on Equity
-43.90%
Revenue Growth
-20.34%
EPS
$-0.51
Balance Sheet
Current Ratio
7.64
Quick Ratio
7.30
Debt/Equity
0.05
Cash & Equivalents
$215.00M
Other
Beta (Volatility)
3.15
Does QSI Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability depends heavily on the successful commercialization and widespread adoption of its Proteus platform, and the ability to continually innovate and protect its intellectual property from emerging competitors. Early lead in a novel technology offers a temporary advantage.
Moat Erosion Risks
- •Rapid technological advancements by competitors that could render Quantum-Si's technology obsolete or less competitive.
- •Failure to achieve widespread market adoption for Proteus, limiting the entrenchment of switching costs.
- •Challenges in defending or expanding its IP portfolio against potential infringers or new entrants.
QSI Competitive Moat Analysis
Sign up to see competitive advantages
QSI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, with a mix of long-term bullish speculation and short-term bearish sentiment due to price depreciation and financial concerns.
Institutional Sentiment
Neutral to Negative. Reflected by Canaccord's price target downgrade and 'Hold' rating. Some bullish analyst targets (81.3% upside) exist, but specific institutional buying trends are not provided in this research.
Insider Activity (Form 4)
Jeffrey Alan Hawkins (President & CEO) sold 167,424 shares in April 2026 for tax withholding related to RSU vesting. This is not considered discretionary selling and typically does not signal negative outlook.
Options Flow
Normal options activity; no specific unusual put/call ratio or large block trades indicating significant institutional positioning were identified in the search results.
Earnings Intelligence
Next Earnings
2026-05-07
Surprise Probability
Medium
Historical Earnings Pattern
Likely volatile, with the stock price reacting strongly to updates on instrument placements, commercialization progress, and cash burn, given its early-stage and speculative nature.
Key Metrics to Watch
Competitive Position
Top Competitor
ILLUMINA (though different focus, similar disruptive potential in 'omics space)
Market Share Trend
Gaining nascent market share in the emerging single-molecule protein sequencing segment, aiming to carve out a new category rather than directly compete for existing market share from traditional proteomics players.
Valuation vs Peers
Trading at a significant premium on Price/Sales (113.1x vs sector median 3.2x), indicating high investor expectation for future growth rather than current fundamentals. Price/Book is lower than sector median (1.6x vs 2.6x), reflecting its asset base relative to equity, but not profitability.
Competitive Advantages
- •Proprietary single-molecule digital protein sequencing technology (Proteus and Platinum platforms)
- •Strong intellectual property portfolio in a novel field
- •Founder Jonathan Rothberg's track record of disruptive innovation in life sciences
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive QSI Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 7, 2026)
- •Further updates on Proteus commercial launch and early customer feedback (Q2/Q3 2026)
- •Participation in upcoming investor conferences
Medium-Term (6-18 months)
- •Significant customer acquisition for Proteus platform
- •Strategic partnerships with key pharmaceutical or research institutions (H2 2026 / H1 2027)
- •Expansion of Proteus applications and software capabilities
Long-Term (18+ months)
- •Disruption and market leadership in the multi-billion-dollar proteomics sequencing market
- •Broad adoption of single-molecule protein sequencing in drug discovery and diagnostics
- •Demonstration of clinical utility for Proteus technology
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for QSI?
- ✓
Acceleration in Proteus instrument placements and consumable sales growth.
- ✓
Improvements in gross margins and a clear, credible path to cash flow positivity.
- ✓
New strategic partnerships or major customer wins.
Bull Case Analysis
See what could go right with Premium
Competing with QSI
See how Quantum-Si Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Quantum-Si Inc QSI | $207.3M | 6.5 | 4.5 | $3.1M | -4160.1% | -20.3% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Quantum-Si Inc Makes Money
Quantum-Si generates revenue primarily by selling its proprietary 'Platinum' and upcoming 'Proteus' digital protein sequencing instruments (hardware) to researchers in academia, biotech, and pharmaceutical companies. Once customers have the instruments, the company makes recurring revenue from the sale of consumable chips and reagents essential for running experiments, similar to a 'razor-and-blade' model. This model aims to drive high-margin, sticky revenue from ongoing consumable sales after the initial hardware placement.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Quantum-Si Inc (QSI)?
As of May 3, 2026, Quantum-Si Inc has a DVR Score of 6.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Quantum-Si Inc?
Quantum-Si Inc's market capitalization is approximately $207.3M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Quantum-Si Inc use?
QSI is the ticker symbol for Quantum-Si Inc. The company trades on the NGM.
What is the risk level for QSI stock?
Our analysis rates Quantum-Si Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of QSI?
Quantum-Si Inc currently has a price-to-earnings (P/E) ratio of 4.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Quantum-Si Inc's revenue growing?
Quantum-Si Inc has reported revenue growth of -20.3%. Revenue has been declining, which warrants closer examination.
Is QSI stock profitable?
Quantum-Si Inc has a profit margin of -4160.1%. The company is currently unprofitable.
How often is the QSI DVR analysis updated?
Our AI-powered analysis of Quantum-Si Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for QSI (Quantum-Si Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.